Results 181 to 190 of about 18,017 (247)

Factor Xa inhibitors versus low-molecular-weight heparin for preventing coagulopathy following COVID-19: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Amin L, Qayyum K, Uzair M, Khan F, Sethi P, Hanif L, Azhar A, Mazhar S, Ejaz U, Jawad S.   +9 more
europepmc   +1 more source

Factor Xa inhibitors versus warfarin in patients with non-valvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Zahoor MM, Mazhar S, Azhar A, Mand Khan F, Anees U, Vohra RR, Ejaz U, Jawad S.   +7 more
europepmc   +1 more source

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE.   +7 more
europepmc   +1 more source

Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study. [PDF]

Eur Stroke J
Diener HC, Grosse GM, Hüsing A, Stang A, Kuklik N, Brinkmann M, Maurer GD, Soda H, Pohlmann C, Hilker-Roggendorf R, Popovic N, Kraft P, Mackert BM, Eschenfelder CC, Weimar C.   +14 more
europepmc   +1 more source

Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program. [PDF]

Int J Surg
Chan SY, Huang JF, Cheng CT, Hsu CP, Liao CH, Fu CY.   +5 more
europepmc   +1 more source

Factor Xa inhibitors

Hämostaseologie, 2009
SummaryOral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest developments of oral direct FXa inhibitors and focuses on those which have been approved for the prevention of venous thromboembolism (VTE) after total hip or knee replacement or are in advanced development and have passed phase ...
E. Perzborn
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Anthranilamide inhibitors of factor Xa

Bioorganic & Medicinal Chemistry Letters, 2007
SAR about the B-ring of a series of N(2)-aroyl anthranilamide factor Xa (fXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays.
David, Mendel, Angela L, Marquart, Sajan, Joseph, Philip, Waid, Ying K, Yee, Anne Louise, Tebbe, Andrew M, Ratz, David K, Herron, Theodore, Goodson, John J, Masters, Jeffry B, Franciskovich, Jennifer M, Tinsley, Michael R, Wiley, Leonard C, Weir, Jeffrey A, Kyle, Valentine J, Klimkowski, Gerald F, Smith, Richard D, Towner, Larry L, Froelich, John, Buben, Trelia J, Craft   +20 more
openaire   +2 more sources

Factor Xa Inhibitors

Current Pharmaceutical Design, 1996
Thrombin occupies a central position in thrombus formation and eventually has been a target to develop anticoagulant agents. Although both heparin and warfarin have been used as anticoagulants, a more useful, ideal anticoagulant is desired at bedside.
Satoshi Kunitada, Takayasu Nagahara
openaire   +1 more source